Vertex Pharmaceuticals (VRTX) Income from Non-Controlling Interests (2011 - 2018)

Vertex Pharmaceuticals' Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at -$25.4 million for Q4 2018.

• On a quarterly basis, Income from Non-Controlling Interests fell 1794.27% year-over-year to -$25.4 million in Q4 2018; TTM through Sep 2019 was -$25.4 million, a 248.38% decrease from a year earlier, with the FY2018 full-year figure at -$9.8 million, up 94.3% from the prior year.
• Income from Non-Controlling Interests slipped to -$25.4 million in Q4 2018 per VRTX's latest filing, from -$290000.0 in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $28.4 million in Q2 2016 and bottomed at -$188.3 million in Q3 2017.
• The 5-year median for Income from Non-Controlling Interests is -$98000.0 (2015), against an average of -$10.7 million.
• Across the five-year window, Income from Non-Controlling Interests jumped 5741.84% in 2016 and tumbled 26956.75% in 2017, its largest moves.
• Year by year, Income from Non-Controlling Interests stood at $4.2 million in 2014, then tumbled by 122.39% to -$938000.0 in 2015, then plunged by 452.88% to -$5.2 million in 2016, then surged by 128.94% to $1.5 million in 2017, then sank by 1794.27% to -$25.4 million in 2018.
• Per Business Quant, the three latest VRTX Income from Non-Controlling Interests figures stand at -$25.4 million (Q4 2018), -$290000.0 (Q3 2018), and -$1.1 million (Q2 2018).